1.
Cascorbi I: Arzneimittelinteraktionen. Prinzipien, Beispiele und klinische Folgen. Dtsch Arztebl, 2012; 109 (44–34): 546–56.
2.
Tampi RR, Balderas M, Carter KV, et al.: Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics 2015; 56 (1): 36–43.
3.
Lundbeck GmbH. Rote Hand Brief: Zusammenhang von CIPRAMIL (Citalopramhydrobromid/ Citalopram-hydrochlorid) mit dosisabhängiger QT-Intervall-Verlängerung. 2011; (4089127861): 2–4.
4.
Lundbeck GmbH. Rote Hand Brief: Zusammenhang von Escitalopram (Cipralex) mit dosisabhängiger QT-Intervall-Verlängerung. 2011; (4089127861): 1–3.
5.
Grandt D, Lappe V: Arzneimittelreport 2018 Schriftenreihe Zur Gesundheitsanalyse. 2018.
6.
Zeltser D, Justo D, Halkin A, et al.: Torsade de Pointes Due to Noncardiac Drugs. Medicine (Baltimore) 2003; 82 (4): 282–90.
7.
Pollock BG: Citalopram: a comprehensive review. Expert Opin Pharmacother 2001; 2 (4): 681–98.
8.
Roden DM : Drug-Induced Prolongation of the QT Interval. NEJM 2004; 350 (10): 1013–22.
9.
Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM 2008; 358:1547–59.
10.
Parving HH, Brenner BM, McMurray JJ, et al.: Baseline characteristics in the Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13: 387–93.
11.
Krüger B, Benck U, Singer T, Krämer B: Nierenfunktionsstörungen durch Medikamente. DMW 2012; 137: 1873–7.
12.
Henrich WL, Agodoa LE, Barrett B, et al.: Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committe of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162–5.
13.
Ungprasert P, Cheungpasitporn W, Crowson CS, et al.: Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and metaanalysis of observational studies. Eur J
Intern Med 2015; 26: 285–91.
14.
Dreischulte T, Morales DR, Bell S, et al.: Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015; 88: 396–403.
15.
Lapi F, Azoulay L, Yin H, et al.: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013; 346: e8525.
16.
Loboz KK, Shenfield GM: Drug combinations and impaired renal function – the ‘triple whammy’. Br J Clin Pharmacol 2005; 59:239–43.
17.
Gutthann SP, Rodríguez LAG, Raiford DS, et al.: Nonsteroidal Anti-inflammatory Drugs and the Risk of Hospitalization for Acute Renal Failure. Arch Intern Med 1996; 156: 2433–9.
18.
Fournier JP, Lapeyre-Mestre M, Sommet A, et al.: Laboratory Monitoring of Patients Treated with Antihypertensive Drugs and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs: A Cohort Study. Burdmann EA (Hrsg.): PLoS ONE 2012; 7: e34187.
19.
Grandt D, Lappe V: Arzneimittelreport 2018 Schriftenreihe zur Gesundheitsanalyse. 2018.
20.
Kern WV: Antibiotika und antibakterielle Chemotherapeutika. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J, editors. Arzneiverordnungs-Report 2019. Berlin, Heidelberg: Springer Berlin Heidelberg; 2019: 435–59.
21.
Hallberg P, Marten L, Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol. 2006; 62 (6): 491–2.
22.
Horton R, Barber C: Opioid-induced respiratory depression resulting from transdermaln fentanyl-clarithromycin drug interaction in a patient with advanced COPD. J Pain Symptom Manage 2009; 37 (6): e2–5.
23.
Mercadante S, Villari P, Ferrera P: Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage 2002; 24 (3): 284–6.
24.
Cronnolly B, Pegrum H: Fentanyl-clarithromycin interaction. BMJ Case Rep. 2012; 2012.
25.
Liukas A, Hagelberg NM, Kuusniemi K, et al.: Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol. 2011; 31 (3): 302–8.
26.
Tempelhoff R, Modica PA, Spitznagel EL, Jr: Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth 1990; 37 (3): 327–32.
27.
Niwa T, Imagawa Y, Yamazaki H: Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Current drug metabolism 2014; 15 (7): 651–79.
28.
AWMF: S2k-Leitlinie: Tuberkulose im Erwachsenenalter. 2017. www.awmf. org/upload /tx_szleitlinien/020–019l_S2k_ Tuberkulose_im_Erwachsenen-alter_2017–11.pdf.
29.
WHO: Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 update. www.who.int/tb/publications/2017/dstb_guidance_2017/en/.
30.
Hoiby N, Bjarnsholt T, Moser C, et al.: ESCMID Guideline for the diagnosis and treatment of biofilm infections 2014. CMI 2015; 21 (S1): S1–25.
31.
Eljaaly K, Alshehri S, Bhattacharjee S, et al.: Contraindicated drug-drug interactions associated with oral antimicrobial agents prescribed in the ambulatory care setting in the United States. CMI 2019; 25: 620–22.
32.
Finch CK, Chrisman CR, Baciewicz A, et al.: Rifampin and Rifabutin Drug Interactions – An Update. JAMA 2002; 162: 985–92.
33.
Kim KY, Epplen K, Foruhari F, et al.: Update on the interaction of rifampicin and warfarin. Prog Cardiovasc Nurs 2007; 22 (2): 97–100.
34.
Mizera L, Geisler T, Mörike K, et al.: Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists. BMJ Case Reports 2018: bcr2016215155.
35.
Rogers KC, Neu DW, Jaeger MC, et al.: An underappreciated and prolonged drug interaction leads to ineffective anticoagulation. South Med J 2019; 112 (2): 125–9.
36.
Narum S, Westergren T, Klemp M: Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMC Open 2014; 4: e004587.
37.
Piper JM, Ray WA, Daugherty JR, Griffin MR et al.: Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735–40.
38.
Fischbach WPM, Lynen Jansen P, Bolten W, et al.: S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016; 53: 327–63.
39.
Koop H, Labenz J: Ulkuskrankheit – Update. Gastroenterol up2date 2016; 12: 193–206.
40.
Scarpingnato C, Gatta L, Zullo A, et al.: Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med 2016; 14: 179.
41.
Masclee GM, Valkhoff VE, Coloma PM, et al.: Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147: 784–92.
42.
Rodriguez LAG, Hernandez-Diaz S: The risk of upper gastrointestinal complications associated with anti-inflammatory drugs, corticosteroids, acetaminophen, and combinations of these agents. Arthritis Res 2001; 3: 96–101.
43.
Weil J, Langman MJS, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with nonsteroidal anti-inflammatory drugs. Gut 2000; 46: 27–31.
44.
Hasenfuß G, Fölsch UR: Klug entscheiden: Rationale, Umsetzung, Evaluation. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen ZEFQ; Volume 129, Dezember 2017, 37–40
45.
Hasenfuß G, Märker-Herrmann E, Halle M, et al.: Gegen Unter- und Überversorgung. Dtsch Arztebl 2016; 113 (13) (Sonderdruck).
46.
Wilcock A, Thomas J, Frisby J, et al.: Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit. British Journal of Clinical Pharmacology 2005; 60 (3): 326–9.
47.
Kotlinska-Lemieszek A, Paulsen O, Kaasa S, et al.: Polypharmacy in Patients With Advanced Cancer and Pain: A European Cross-sectional Study of 2282 Patients. Pain Symptom Manage 2014; 48 (6): 1145–59.
48.
YouScript [Internet]. 2020 [cited 22 July 2020]. Available from: www.youscript.com.